The U.S. Supreme Court seems inclined not to restrict access to the abortion pill, indicating skepticism towards anti-abortion groups and doctors challenging its usage due to concerns regarding legal standing.
At the heart of the matter are FDA regulations regarding the prescription and distribution of mifepristone. The FDA’s actions in question include extending the period for medication abortions and permitting mail delivery of the drug without an in-person clinician visit, significantly altering access to abortion services.
During the arguments, justices focused on whether the challengers had legitimate legal standing to contest the FDA’s actions.
The plaintiffs argued potential violations of conscience due to handling emergency complications arising from ...